Henry James International Management’s Autolus Therapeutics AUTL Stock Holding History

Henry James International Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-54,047	Closed	-$281K	–	124
2021 Q4	$281K	Hold	54,047	–	–	0.09%	128
2021 Q3	$354K	Hold	54,047	–	–	0.11%	123
2021 Q2	$359K	Hold	54,047	–	–	0.1%	133
2021 Q1	$310K	Buy	+54,047	New	+$400K	0.09%	148

Other funds holding AUTL

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Henry James International Management's AUTL Position: Q1 2022 in Review

Henry James International Management sold out of Autolus Therapeutics (AUTL) in Q1 2022, closing a stake of 54,047 shares — an estimated $281K sold.

Henry James International Management first reported a position in AUTL in Q1 2021 and held it in 4 quarters. The position peaked at $359K in Q2 2021. 66 funds tracked by Wall St. Rank hold AUTL as of Q1 2022.

Henry James International Management reported no remaining Autolus Therapeutics position as of Q1 2022 after selling out during the quarter.
Henry James International Management sold 54,047 Autolus Therapeutics shares in Q1 2022, an estimated $281K.
Henry James International Management first reported a position in Autolus Therapeutics in Q1 2021 and held it in 4 quarters.
Henry James International Management's Autolus Therapeutics position peaked at $359K in Q2 2021.
66 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2022.

Based on Henry James International Management's 13F filing for Q1 2022, filed 21 Apr 2022.